Scarica l'app Stockscreener
23.64
3.55%
-0.87
Dopo l'orario di chiusura:
23.55
-0.09
-0.38%
Precedente Chiudi:
$24.51
Aprire:
$24.09
Volume 24 ore:
192.71K
Relative Volume:
0.75
Capitalizzazione di mercato:
$1.14B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-7.6384
EPS:
-3.0949
Flusso di cassa netto:
-
1 W Prestazione:
-10.45%
1M Prestazione:
+6.63%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$23.50
$25.38
Intervallo di 1 settimana:
$23.50
$29.05
Portata 52W:
$15.10
$29.05
Odyssey Therapeutics Inc Stock (ODTX) Company Profile
Nome
Odyssey Therapeutics Inc
Settore
Industria
Telefono
(212) 841-1000
Indirizzo
51 SLEEPER STREET, BOSTON
Compare ODTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ODTX
Odyssey Therapeutics Inc
|
23.64 | 1.18B | 0 | 0 | 0 | -3.0949 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Odyssey Therapeutics Inc Borsa (ODTX) Ultime notizie
Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Receives Average Rating of "Moderate Buy" from Analysts - marketbeat.com
Odyssey Therapeutics’ OD-001 Meets Key Endpoints in Ulcerative Colitis Trial - Minichart
symbol__ Stock Quote Price and Forecast - CNN
Oral ulcerative colitis drug at Odyssey (ODTX) put 27% of patients in remission—larger trials are planned - Stock Titan
Odyssey Therapeutics posts September 2026 presentation detailing OD-001 Phase 2a success, $433M cash runway into H2 2028 - TradingView
ODTX Forecast & Price Target - TradingKey
ODTX Price Today: Odyssey Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
RIPK2 inhibitors reported in Odyssey Therapeutics patent - BioWorld News
Odyssey Therapeutics Hits $900M Valuation In Nasdaq Debut, Stock Climbs 13% Before Diving Lower - Stocktwits
Odyssey Therapeutics, Inc. Common Stock (NASDAQ: ODTX) Stock Price, News & Analysis - Kalkine
Q3 Earnings Forecast for ODTX Issued By HC Wainwright - marketbeat.com
Odyssey Therapeutics to Participate in Upcoming Investor Conferences - Moomoo
This Ascendis Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Sahm
Top Odyssey Therapeutics (ODTX) Competitors 2026 - MarketBeat
Odyssey Therapeutics (ODTX) Stock Trends and Sentiment 2026 - marketbeat.com
J.P. Morgan Maintains Odyssey Therapeutics(ODTX.US) With Buy Rating, Raises Target Price to $29 - Moomoo
Odyssey Therapeutics (ODTX) Looks Fully Valued As Earnings And Evotec Deal Refocus Attention - Yahoo Finance
Odyssey Therapeutics (ODTX) Stock Looks Reasonable As AI Research News Lands - Sahm
Evotec and Odyssey Forge AI-Powered Drug Discovery Pact Targeting Autoimmune Diseases - finance.biggo.com
Odyssey Therapeutics (NASDAQ:ODTX) Given New $29.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Analysts Offer Insights on Healthcare Companies: Biodesix (BDSX), Pacific Biosciences (PACB) and Odyssey Therapeutics, Inc. (ODTX) - theglobeandmail.com
EQS-News: Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - sharewise.com
Odyssey Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Odyssey Therapeutics, Inc. Q2 2026: Revenue $0 EPS $(1.74) — 10-Q Summary - TradingView
Biotech Stocks At 52-Week HighsBVS, TVTX, ODTX, CRL Climb With Q2 Results, ACRS - RTTNews
Evotec and Odyssey Pair AI With Lab Tests for Immune Diseases - Stock Titan
Evotec Se and Odyssey Therapeutics, Inc. Enter Ai-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - marketscreener.com
Evotec : and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - marketscreener.com
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - Yahoo Finance
Odyssey Therapeutics (ODTX) Institutional Ownership 2026 - marketbeat.com
Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Odyssey Therapeutics reports Q2 2026 net loss $52.8M; cash $433.1M to fund into 2H 2028 - TradingView
Odyssey Therapeutics, Inc. Revenue Breakdown – NASDAQ:ODTX - TradingView
Odyssey Therapeutics Ord Shs (Proposed) (ODTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ODTX|Odyssey Therapeutics Ord Shs (Proposed)|Price:18.660|Chg%:+0.990 - TradingKey
Odyssey Therapeutics (ODTX) Earnings Date and Reports 2026 - MarketBeat
Enterprise value to EBITDA forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
Enterprise value to revenue forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
Price to book forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
Price to earnings forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
Price to sales forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
Odyssey Therapeutics prices upsized IPO at $18 per share - Investing.com
Odyssey Therapeutics Inc (ODTX) Dividend News Alerts - DividendInvestor.com
Enterprise value to EBIT forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
Odyssey Therapeutics Inc Azioni (ODTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):